Nokia Corp vs Sanofi SA — how do they compare? Nokia Corp trades at $10.93 (market cap $56.70B), while Sanofi SA trades at $44.05 (market cap $104.83B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.5%). Which is the better fit depends on your goals.
| NOK | SNY | |
|---|---|---|
Market Cap | $56.70B | $104.83B |
Sector | Technology | Health |
52-Week High | $16.83 | $52.34 |
52-Week Low | $4.05 | $41.33 |
Enterprise Value | $53.51B | $121.32B |
Dividend Yield | 1.63% | 5.5% |
Trailing returns across standard periods
Latest headlines on both assets
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →